A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions

Clear Cell TumorGynecologic CancerAdvanced Cancer

Interventions

DRUG

Pembrolizumab

3 weekly cycles of Pembrolizumab administered by IV

Trial Locations (5)

Western General Hospital, Edinburgh

University College Hospital, London

The Christie Hospital, Manchester

Mount Vernon Hospital, Northwood

Churchill Hospital, Oxford

All Listed Sponsors

lead

University College, London

OTHER

NCT03425565 - A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer | Biotech Hunter | Biotech Hunter